Synergistic activity of everolimus and 5-aza-2′-deoxycytidine in medullary thyroid carcinoma cell lines

Giovanni Vitale, Alessandra Dicitore, Daniele Pepe, Davide Gentilini, Elisa S. Grassi, Maria O. Borghi, Giulia Gelmini, Maria C. Cantone, Germano Gaudenzi, Gabriella Misso, Anna M. Di Blasio, Leo J. Hofland, Michele Caraglia, Luca Persani

Research output: Contribution to journalArticle

Abstract

Medullary thyroid cancer (MTC) is a tumor highly resistant to chemo- and radiotherapy. Drug resistance can be induced by epigenetic changes such as aberrant DNA methylation. To overcome drug resistance, we explored a promising approach based on the use of 5-aza-2′-deoxycytidine (AZA), a demethylating agent, in combination with the mTOR inhibitor everolimus in MTC cells (MZ-CRC-1 and TT). This combined treatment showed a strong synergistic antiproliferative activity through the induction of apoptosis. The effect of everolimus and/or AZA on genome-wide expression profiling was evaluated by Illumina BeadChip in MZ-CRC-1 cells. An innovative bioinformatic pipeline identified four potential molecular pathways implicated in the synergy between AZA and everolimus: PI3K-Akt signaling, the neurotrophin pathway, ECM/receptor interaction, and focal adhesion. Among these, the neurotrophin signaling pathway was most directly involved in apoptosis, through the overexpression of NGFR and Bax genes. The increased expression of genes involved in the NGFR-MAPK10-TP53-Bax/Bcl2 pathway during incubation with AZA plus everolimus was validated by western blotting in MZ-CRC-1 cells. Interestingly, addition of a neutralizing anti-NGFR antibody inhibited the synergistic cytotoxic activity between AZA and everolimus. These results open a new therapeutic scenario for MTC and potentially other neuroendocrine tumors, where therapy with mTOR inhibitors is currently approved.

Original languageEnglish
Pages (from-to)1007-1022
Number of pages16
JournalMolecular Oncology
Volume11
Issue number8
DOIs
Publication statusPublished - Aug 1 2017

Fingerprint

decitabine
Cell Line
Nerve Growth Factors
Drug Resistance
Apoptosis
Focal Adhesions
Neuroendocrine Tumors
DNA Methylation
Neutralizing Antibodies
Computational Biology
Phosphatidylinositol 3-Kinases
Epigenomics
Anti-Idiotypic Antibodies
Radiotherapy
Therapeutics
Western Blotting
Medullary Thyroid cancer
Everolimus
Genome
Gene Expression

Keywords

  • 5-aza-2′-deoxycytidine
  • everolimus
  • medullary thyroid cancer
  • mTOR
  • neurotrophin pathway
  • NGFR

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Cancer Research

Cite this

Synergistic activity of everolimus and 5-aza-2′-deoxycytidine in medullary thyroid carcinoma cell lines. / Vitale, Giovanni; Dicitore, Alessandra; Pepe, Daniele; Gentilini, Davide; Grassi, Elisa S.; Borghi, Maria O.; Gelmini, Giulia; Cantone, Maria C.; Gaudenzi, Germano; Misso, Gabriella; Di Blasio, Anna M.; Hofland, Leo J.; Caraglia, Michele; Persani, Luca.

In: Molecular Oncology, Vol. 11, No. 8, 01.08.2017, p. 1007-1022.

Research output: Contribution to journalArticle

Vitale, Giovanni ; Dicitore, Alessandra ; Pepe, Daniele ; Gentilini, Davide ; Grassi, Elisa S. ; Borghi, Maria O. ; Gelmini, Giulia ; Cantone, Maria C. ; Gaudenzi, Germano ; Misso, Gabriella ; Di Blasio, Anna M. ; Hofland, Leo J. ; Caraglia, Michele ; Persani, Luca. / Synergistic activity of everolimus and 5-aza-2′-deoxycytidine in medullary thyroid carcinoma cell lines. In: Molecular Oncology. 2017 ; Vol. 11, No. 8. pp. 1007-1022.
@article{480f002b88e54831943f1b7ef76f533e,
title = "Synergistic activity of everolimus and 5-aza-2′-deoxycytidine in medullary thyroid carcinoma cell lines",
abstract = "Medullary thyroid cancer (MTC) is a tumor highly resistant to chemo- and radiotherapy. Drug resistance can be induced by epigenetic changes such as aberrant DNA methylation. To overcome drug resistance, we explored a promising approach based on the use of 5-aza-2′-deoxycytidine (AZA), a demethylating agent, in combination with the mTOR inhibitor everolimus in MTC cells (MZ-CRC-1 and TT). This combined treatment showed a strong synergistic antiproliferative activity through the induction of apoptosis. The effect of everolimus and/or AZA on genome-wide expression profiling was evaluated by Illumina BeadChip in MZ-CRC-1 cells. An innovative bioinformatic pipeline identified four potential molecular pathways implicated in the synergy between AZA and everolimus: PI3K-Akt signaling, the neurotrophin pathway, ECM/receptor interaction, and focal adhesion. Among these, the neurotrophin signaling pathway was most directly involved in apoptosis, through the overexpression of NGFR and Bax genes. The increased expression of genes involved in the NGFR-MAPK10-TP53-Bax/Bcl2 pathway during incubation with AZA plus everolimus was validated by western blotting in MZ-CRC-1 cells. Interestingly, addition of a neutralizing anti-NGFR antibody inhibited the synergistic cytotoxic activity between AZA and everolimus. These results open a new therapeutic scenario for MTC and potentially other neuroendocrine tumors, where therapy with mTOR inhibitors is currently approved.",
keywords = "5-aza-2′-deoxycytidine, everolimus, medullary thyroid cancer, mTOR, neurotrophin pathway, NGFR",
author = "Giovanni Vitale and Alessandra Dicitore and Daniele Pepe and Davide Gentilini and Grassi, {Elisa S.} and Borghi, {Maria O.} and Giulia Gelmini and Cantone, {Maria C.} and Germano Gaudenzi and Gabriella Misso and {Di Blasio}, {Anna M.} and Hofland, {Leo J.} and Michele Caraglia and Luca Persani",
year = "2017",
month = "8",
day = "1",
doi = "10.1002/1878-0261.12070",
language = "English",
volume = "11",
pages = "1007--1022",
journal = "Molecular Oncology",
issn = "1574-7891",
publisher = "Elsevier",
number = "8",

}

TY - JOUR

T1 - Synergistic activity of everolimus and 5-aza-2′-deoxycytidine in medullary thyroid carcinoma cell lines

AU - Vitale, Giovanni

AU - Dicitore, Alessandra

AU - Pepe, Daniele

AU - Gentilini, Davide

AU - Grassi, Elisa S.

AU - Borghi, Maria O.

AU - Gelmini, Giulia

AU - Cantone, Maria C.

AU - Gaudenzi, Germano

AU - Misso, Gabriella

AU - Di Blasio, Anna M.

AU - Hofland, Leo J.

AU - Caraglia, Michele

AU - Persani, Luca

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Medullary thyroid cancer (MTC) is a tumor highly resistant to chemo- and radiotherapy. Drug resistance can be induced by epigenetic changes such as aberrant DNA methylation. To overcome drug resistance, we explored a promising approach based on the use of 5-aza-2′-deoxycytidine (AZA), a demethylating agent, in combination with the mTOR inhibitor everolimus in MTC cells (MZ-CRC-1 and TT). This combined treatment showed a strong synergistic antiproliferative activity through the induction of apoptosis. The effect of everolimus and/or AZA on genome-wide expression profiling was evaluated by Illumina BeadChip in MZ-CRC-1 cells. An innovative bioinformatic pipeline identified four potential molecular pathways implicated in the synergy between AZA and everolimus: PI3K-Akt signaling, the neurotrophin pathway, ECM/receptor interaction, and focal adhesion. Among these, the neurotrophin signaling pathway was most directly involved in apoptosis, through the overexpression of NGFR and Bax genes. The increased expression of genes involved in the NGFR-MAPK10-TP53-Bax/Bcl2 pathway during incubation with AZA plus everolimus was validated by western blotting in MZ-CRC-1 cells. Interestingly, addition of a neutralizing anti-NGFR antibody inhibited the synergistic cytotoxic activity between AZA and everolimus. These results open a new therapeutic scenario for MTC and potentially other neuroendocrine tumors, where therapy with mTOR inhibitors is currently approved.

AB - Medullary thyroid cancer (MTC) is a tumor highly resistant to chemo- and radiotherapy. Drug resistance can be induced by epigenetic changes such as aberrant DNA methylation. To overcome drug resistance, we explored a promising approach based on the use of 5-aza-2′-deoxycytidine (AZA), a demethylating agent, in combination with the mTOR inhibitor everolimus in MTC cells (MZ-CRC-1 and TT). This combined treatment showed a strong synergistic antiproliferative activity through the induction of apoptosis. The effect of everolimus and/or AZA on genome-wide expression profiling was evaluated by Illumina BeadChip in MZ-CRC-1 cells. An innovative bioinformatic pipeline identified four potential molecular pathways implicated in the synergy between AZA and everolimus: PI3K-Akt signaling, the neurotrophin pathway, ECM/receptor interaction, and focal adhesion. Among these, the neurotrophin signaling pathway was most directly involved in apoptosis, through the overexpression of NGFR and Bax genes. The increased expression of genes involved in the NGFR-MAPK10-TP53-Bax/Bcl2 pathway during incubation with AZA plus everolimus was validated by western blotting in MZ-CRC-1 cells. Interestingly, addition of a neutralizing anti-NGFR antibody inhibited the synergistic cytotoxic activity between AZA and everolimus. These results open a new therapeutic scenario for MTC and potentially other neuroendocrine tumors, where therapy with mTOR inhibitors is currently approved.

KW - 5-aza-2′-deoxycytidine

KW - everolimus

KW - medullary thyroid cancer

KW - mTOR

KW - neurotrophin pathway

KW - NGFR

UR - http://www.scopus.com/inward/record.url?scp=85021238302&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021238302&partnerID=8YFLogxK

U2 - 10.1002/1878-0261.12070

DO - 10.1002/1878-0261.12070

M3 - Article

AN - SCOPUS:85021238302

VL - 11

SP - 1007

EP - 1022

JO - Molecular Oncology

JF - Molecular Oncology

SN - 1574-7891

IS - 8

ER -